Cost‐effectiveness of rapid hepatitisCvirus (HCV) testing and simultaneous rapidHCVandHIVtesting in substance abuse treatment programs
Addiction2014Vol. 110(1), pp. 129–143
Citations Over TimeTop 12% of 2014 papers
Bruce R. Schackman, Jared A. Leff, Devra M. Barter, Madeline A. DiLorenzo, Daniel J. Feaster, Lisa R. Metsch, Kenneth A. Freedberg, Benjamin P. Linas
Abstract
On-site rapid hepatitis C virus and HIV testing in substance abuse treatment programs is cost-effective at a <$100,000/quality-adjusted life year threshold.
Related Papers
- → Breaking Down the Barriers to Hepatitis C Virus (HCV) Treatment Among Individuals With HCV/HIV Coinfection: Action Required at the System, Provider, and Patient Levels(2013)180 cited
- → Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection(2017)175 cited
- → Failure of Hepatitis C Therapy in HIV‐Coinfected Drug Users Is Not Due to a Shift in Hepatitis C Virus Genotype(2005)8 cited
- → Treatment of Hepatitis C Virus in the Coinfected Patient(2003)3 cited
- → Development of Neutralization Assay using Murine Leukemia Virus (MuLV) Pseudotyped with Japanese encephalitis Virus (JEV) env Gene(2007)